抗体偶联药物:急诊医师必须知晓的毒性与不良反应
本文综述了美国已批准用于癌症治疗的抗体偶联药物的已知毒性与并发症,重点介绍其急诊表现与处理。多数抗体偶联药物可引起腹泻、恶心呕吐、皮疹、周围神经病变和血细胞减少,一般按标准治疗处理。曲妥珠单抗德鲁替康和索米妥昔单抗可引起间质性肺病,可能类似肺炎并导致呼吸衰竭和死亡,急诊治疗包括氧疗、通气支持和糖皮质激素。伊珠单抗奥唑米星和吉妥珠单抗奥唑米星与肝窦阻塞综合征相关,表现为体重增加、液体超负荷和黄疸。作者指出需进一步研究以确定罕见并发症的真实世界发生率及患者就诊急诊科频率。
要点
- 曲妥珠单抗德鲁替康和索米妥昔单抗可致间质性肺病,可能类似肺炎并导致呼吸衰竭和死亡,急诊治疗包括氧疗、通气支持和糖皮质激素。
- 伊珠单抗奥唑米星和吉妥珠单抗奥唑米星与肝窦阻塞综合征相关,表现为体重增加、液体超负荷和黄疸,近期使用这些药物者肝功能异常应谨慎评估。
- 恩夫妥单抗维多汀或维布妥昔单抗治疗患者可发生高血糖,有时表现为糖尿病酮症酸中毒。
- 替索妥单抗维多汀和曲妥珠单抗美坦新偶联物与出血相关,多数轻微,但已发生严重出血和颅内出血。
- 多种抗体偶联药物可引起类过敏性输注反应,最常见于输注中或输注后不久,但可能延迟至24小时。
适用人群与场景
- 正在接受或近期接受过美国已批准用于癌症治疗的抗体偶联药物(包括曲妥珠单抗德鲁替康、索米妥昔单抗、伊珠单抗奥唑米星、吉妥珠单抗奥唑米星、曲妥珠单抗美坦新偶联物、恩夫妥单抗维多汀、维布妥昔单抗、替索妥单抗维多汀、泊洛妥珠单抗维多汀等)并出现急症表现的患者。
处置流程与药物剂量
- 间质性肺病的急诊治疗包括氧疗、通气支持和糖皮质激素。
- 大多数抗体偶联药物引起的腹泻、恶心呕吐、皮疹、周围神经病变和血细胞减少一般按标准治疗处理。
红旗征与不能漏的情况
- 间质性肺病可类似肺炎并导致呼吸衰竭和死亡,见于曲妥珠单抗德鲁替康和索米妥昔单抗。
- 肝窦阻塞综合征是潜在致命的肝功能障碍,表现为体重增加、液体超负荷和黄疸,见于伊珠单抗奥唑米星和吉妥珠单抗奥唑米星;近期使用这些药物者肝功能异常应谨慎评估。
- 进行性多灶性白质脑病已报告于维布妥昔单抗和泊洛妥珠单抗维多汀。
- 肿瘤溶解综合征可能发生于吉妥珠单抗奥唑米星、泊洛妥珠单抗维多汀和维布妥昔单抗治疗后。
- 恩夫妥单抗维多汀或维布妥昔单抗治疗患者可发生高血糖,有时表现为糖尿病酮症酸中毒。
- 替索妥单抗维多汀和曲妥珠单抗美坦新偶联物与出血相关,多数轻微,但已发生严重出血和颅内出血。
- 类过敏性输注反应最常见于输注中或输注后不久,但可能延迟至24小时。
研究设计与关键结果
- 本文为综述,汇总美国已批准用于癌症治疗的抗体偶联药物的已知毒性与并发症,重点介绍急诊表现与处理;多数抗体偶联药物可引起腹泻、恶心呕吐、皮疹、周围神经病变和血细胞减少,一般按标准治疗处理。
- 间质性肺病(可能类似肺炎并导致呼吸衰竭和死亡)见于曲妥珠单抗德鲁替康和索米妥昔单抗;急诊治疗包括氧疗、通气支持和糖皮质激素。
- 肝窦阻塞综合征(潜在致命,表现为体重增加、液体超负荷和黄疸)见于伊珠单抗奥唑米星和吉妥珠单抗奥唑米星;近期使用这些药物者肝功能异常应谨慎评估。
- 抗体偶联药物心脏不良事件罕见,但曲妥珠单抗美坦新偶联物和曲妥珠单抗德鲁替康可能引起心脏收缩力下降,心率校正QT间期延长是曲妥珠单抗德鲁替康的罕见效应。
- 眼不良事件(尤其视物模糊和角膜病变)常见于索米妥昔单抗和替索妥单抗维多汀;进行性多灶性白质脑病已报告于维布妥昔单抗和泊洛妥珠单抗维多汀。
- 肿瘤溶解综合征可能发生于吉妥珠单抗奥唑米星、泊洛妥珠单抗维多汀和维布妥昔单抗治疗后;恩夫妥单抗维多汀或维布妥昔单抗治疗患者可发生高血糖,有时表现为糖尿病酮症酸中毒。
- 替索妥单抗维多汀和曲妥珠单抗美坦新偶联物与出血相关,多数轻微,但已发生严重出血和颅内出血。
- 多种抗体偶联药物可引起类过敏性输注反应,最常见于输注中或输注后不久,但可能延迟至24小时。
证据类型、等级与局限
- 证据类型:综述。
- 局限:需进一步研究以确定罕见并发症的真实世界发生率及这些并发症患者就诊急诊科的频率。
对床旁实践的改变
- 急诊医师应识别抗体偶联药物相关间质性肺病(可类似肺炎并致呼吸衰竭和死亡),并给予氧疗、通气支持和糖皮质激素。
- 对近期使用伊珠单抗奥唑米星或吉妥珠单抗奥唑米星且肝功能异常者应谨慎评估肝窦阻塞综合征,其表现为体重增加、液体超负荷和黄疸。
- 使用恩夫妥单抗维多汀或维布妥昔单抗者出现高血糖时应考虑糖尿病酮症酸中毒。
- 使用替索妥单抗维多汀或曲妥珠单抗美坦新偶联物者出现出血时,应注意多数轻微但已发生严重出血和颅内出血。
- 输注中或输注后不久(可能延迟至24小时)出现的类过敏性输注反应应考虑抗体偶联药物所致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Antibody-drug conjugates are novel antineoplastic agents whose use is expanding, both in terms of the number of drugs and the number of patients being treated. This article reviews the known toxicities and complications of antibody-drug conjugates that are currently approved for the treatment of cancer in the United States, with a focus on their emergency presentation and management. Similar to many other cancer therapies, most antibody-drug conjugates can cause diarrhea, nausea/vomiting, rash, peripheral neuropathy, and cytopenia, which are generally treated following standard-of-care. Interstitial lung disease, which may mimic pneumonia and cause respiratory failure and death, has been seen with trastuzumab deruxtecan and mirvetuximab soravtansine; emergency treatment of this condition includes oxygenation, ventilatory support, and corticosteroids. Inotuzumab ozogamicin and gemtuzumab ozogamicin are both associated with sinusoidal obstruction syndrome, a potentially fatal liver dysfunction that presents with weight gain, fluid overload, and jaundice. Abnormal liver function tests in patients who have been recently treated with these agents should be cautiously evaluated. Cardiac adverse events with antibody-drug conjugates are rare, but trastuzumab emtansine and trastuzumab deruxtecan may cause a decrease in cardiac contractility, and heart rate corrected QT interval prolongation is a rare effect of trastuzumab deruxtecan. Ocular adverse events, especially blurred vision, and keratopathy, are common with mirvetuximab soravtansine and tisotumab vedotin. Progressive multifocal leukoencephalopathy has been reported with brentuximab vedotin and polatuzumab vedotin. Tumor lysis syndrome may occur after treatment with gemtuzumab ozogamicin, polatuzumab vedotin, and brentuximab vedotin. Patients receiving enfortumab vedotin or brentuximab vedotin may develop hyperglycemia, sometimes presenting as diabetic ketoacidosis. Tisotumab vedotin and trastuzumab emtansine are associated with bleeding; although it is minor in most cases, severe bleeding and intracranial hemorrhage have occurred. Several antibody-drug conjugates can cause an anaphylactoid infusion-related reaction, which occurs most commonly during or soon after infusion but may be delayed up to 24 hours. Further research is needed to establish the real-world incidence of rare complications and how often patients with these complications present to the emergency department.
参考来源
- Markides DM, Hita AG, Merlin J, et al. Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know. Ann Emerg Med. 2024. PMID: 39641680. doi:10.1016/j.annemergmed.2024.10.015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。